knowledge -WSS

knowledge

author：leisure time 2025-10-02 20:48:09 - browse：2

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Winners, losers from Medicare’s list of drugs subject to price talks

entertainment

explore

WSS

What do new weight loss drugs mean for bariatric surgery?

How to protect coverage of PrEP

The response to Covid

4 missing after record

In science, is the line between industry and academia shifting?

What Henrietta Lacks's story taught me about my role as a doctor

knowledge

knowledge

knowledge

Affirmative action in medical school literally saved lives

4 missing after record

Walensky prepares to leave CDC — and Congress — behind

Novartis develops a rapidly manufactured CAR

Trump demands the U.S. pay no more for drugs than other countries … again

Severe heat forecast: Where scorching temperatures will persist over the next week

23andMe had bad news about my health. I wish a person had delivered it

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

After affirmative action ruling, medical educators look to 'holistic review'

Charges dismissed against white woman who spat on Black woman during protests in Connecticut

focus

Study finds new variant for Parkinson’s in African populations

How a key Senate committee is planning to regulate PBMs

Medicare explains how it will choose drugs for negotiation

NYU Langone launches private ChatGPT for its health care data

Doctors have an ethical obligation to be advocates

My chronic pain journey would have been easier knowing 5 things % STAT

entertainment

hotspot

explore

entertainment